Sign Out
HALAVEN monotherapy is indicated for the treatment of adult patients with locally advanced or metastatic breast cancer who have progressed after at least two chemotherapeutic regimens for advanced disease (see Pharmacology: Pharmacodynamics: Clinical efficacy under Actions). Prior therapy should have included an anthracycline and a taxane unless patients were not suitable for these treatments.
HALAVEN is indicated for the treatment of adult patients with unresectable liposarcoma who have received prior anthracycline containing therapy (unless unsuitable) for advanced or metastatic disease (see Pharmacology: Pharmacodynamics under Actions).
